TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector

Transforming growth factor-beta 1 (TGF-beta 1) has previously been implicated as a potential negative autocrine or paracrine growth regulator of certain cell types (Arteaga, C. L., R. J. Coffey, Jr., T. C. Dugger, C. M. McCutchen, H. L. Moses, and R. M. Lyons. 1990. Cell Growth & Differ. 1:367-374; Hafez, M. M., D. Infante, S. Winawer, and E. Friedman. 1990. Cell Growth & Differ. 1:617-626; Glick, A. B., K. C. Flanders, D. Danielpour, S. H. Yuspa, and M. B. Sporn. 1989. Cell Regulation. 1:87-97). This is based mainly on experiments assessing the effects of exogenous TGF-beta 1 or neutralizing antibodies to TGF-beta 1 on normal or tumor cell proliferation in vitro. However, direct evidence demonstrating such a negative regulation of tumor cell growth in vivo is still lacking. To overcome this problem we have constructed and used an antisense expression vector for TGF-beta 1 as a means of regulating endogenous TGF-beta 1 expression in tumor cells. Antisense- transfected FET human colon carcinoma cells showed a fivefold reduction in TGF-beta 1 mRNA and 15-fold reduction in TGF-beta 1 secretion. Antisense mRNA was detected in transfected cells by an RNase protection assay. Compared to control cells, cultured antisense-transfected cells showed a reduction in lag phase time rather than a change in doubling time. Cloning efficiencies of transfected cells were four times greater than control cells in anchorage-independent assays. Control cells did not form tumors at 5 x 10(5) in athymic nude mice. Antisense- transfected cells formed tumors in 40% of animals injected. At higher inocula (1 x 10(6) cells) antisense-transfected cells formed tumors in 100% of animals injected, but control cells still failed to form tumors. These results show that TGF-beta 1 acts as a negative growth regulator of human colon carcinoma cells in vivo as well as in vitro. Acquisition of partial or full resistance to such inhibitory effects may therefore contribute to tumor development and progression.

[1]  K. M. Mulder.  Differential regulation of c-myc and transforming growth factor-alpha messenger RNA expression in poorly differentiated and well-differentiated colon carcinoma cells during the establishment of a quiescent state. , 1991, Cancer research.

[2]  K. M. Mulder,et al.  Inhibitory Effects of Transforming Growth Factor β1 on Mitogenic Response, Transforming Growth Factor α, and c-myc in Quiescent, Well-Differentiated Colon Carcinoma Cells , 1990 .

[3]  K. M. Mulder,et al.  Evidence for c‐myc in the signaling pathway for TGF‐β in well‐differentiated human colon carcinoma cells , 1990 .

[4]  S. Winawer,et al.  Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[5]  R. Coffey,et al.  Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  J. Massagué,et al.  Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation , 1990, Cell.

[7]  R. Derynck,et al.  Human Transforming Growth Factor- β3: Recombinant Expression, Purification, and Biological Activities in Comparison with Transforming Growth Factors-β 1 and -β2 , 1989 .

[8]  M. Sporn,et al.  Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. , 1989, Cell regulation.

[9]  K. M. Mulder,et al.  Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. , 1989, Experimental cell research.

[10]  M. Sporn,et al.  Immunodetection and quantitation of the two forms of transforming growth factor‐beta (TGF‐β1 and TGF‐β2) secreted by cells in culture , 1989 .

[11]  M. Inouye.  Antisense RNA: its functions and applications in gene regulation--a review. , 1988, Gene.

[12]  K. M. Mulder,et al.  Alterations in c‐myc expression in relation to maturational status of human colon carcinoma cells , 1988, International journal of cancer.

[13]  A. Lagarde,et al.  Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts. , 1988, Journal of the National Cancer Institute.

[14]  M. Brattain,et al.  Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. , 1988, Cancer research.

[15]  A. Barbat,et al.  Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. , 1988, Cancer research.

[16]  H. Moses,et al.  Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor-beta 1. , 1987, Cancer research.

[17]  M. Sporn,et al.  Some recent advances in the chemistry and biology of transforming growth factor-beta , 1987, The Journal of cell biology.

[18]  G. Plowman,et al.  Cloning and Sequence Analysis of Simian Transforming Growth Factor-β cDNA , 1987 .

[19]  M. Brattain,et al.  Characterization of the inhibitory effects of transforming growth factor-beta on a human colon carcinoma cell line. , 1987, Cancer research.

[20]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[21]  D. Lawrence,et al.  Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions , 1985 .

[22]  D. Pfarr,et al.  A highly modular cloning vector for the analysis of eukaryotic genes and gene regulatory elements. , 1985, DNA.

[23]  Anita B. Roberts,et al.  Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells , 1985, Nature.

[24]  W I Wood,et al.  Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Brattain,et al.  Characterization of human colon carcinoma cell lines isolated from a single primary tumour. , 1983, British Journal of Cancer.

[26]  I. Pastan,et al.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P Berg,et al.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. , 1982, Journal of molecular and applied genetics.

[28]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[29]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Schaeffer,et al.  Efficient detection of soft agar grown colonies using a tetrazolium salt. , 1976, Cancer letters.

[31]  P. Leder,et al.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. , 1972, Proceedings of the National Academy of Sciences of the United States of America.